Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016923
Chunk: 183

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 183
---
   |
| Balance at December 31, 2024 |     |              | 1,326,861 |   |     | $           | 1.99 |     | $          | 2,636,259 |   |     |                      | 1,072,838 |     |          | 254,023 |   |
| Granted                      |     |              |   253,398 |   |     |             | 0.84 |     |            |   212,875 |   |     |                      |    66,658 |     |          | 186,740 |   |
| Forfeited                    |     |              |   (10,289 | ) |     |             | 0.81 |     |            |    (8,334 | ) |     |                      |         — |     |          | (10,289 | ) |
| Balance at March 31, 2025    |     |              | 1,569,970 |   |     | $           | 2.24 |     | $          | 2,840,800 |   |     |                      | 1,139,496 |     |          | 430,474 |   |

During the three months ended March
31, 2025, the Company issued restricted stock awards (“RSAs”) for an aggregate of 243,109
shares of Common Stock to employees, non-employees, and the board of directors. The shares vest in equal monthly installments over terms
of immediately and up to three years, subject to the employees and non-employees providing continuous service through the vesting date. During the three
months ended March 31, 2025, 92,601
shares vested from RSAs granted prior to January 1, 2025, and 66,658
shares vested from RSAs granted during the three months ended March 31, 2025.

Note 14. WARRANTS

The Company’s outstanding Common
Stock warrants are equity classified. As of March 31, 2025, and December 31, 2024, the Company had 12,873,602
and 12,298,124
warrants outstanding to purchase one share of the Company’s Common Stock for each warrant at a weighted average exercise price
of $2.74
and expire at various dates through February 2030. During the three months ended March 31, 2025,